Highlights of PYC's pipeline
Disease-modifying drug candidates
Each of PYC’s pipeline programs address the root cause of the target disease.
From the kidney to the eye and central nervous system, PYC is building a pipeline that demonstrates the potential for RNA therapeutics across multiple tissues and diseases.
In areas of major unmet need
PYC’s programs target diseases with no established standard of care with market sizes between $1 and $15 billion p.a.
With the highest probability of success
PYC targets monogenic diseases with clearly defined genetic drivers, providing a strong mechanistic rationale and a higher historical likelihood of clinical success than industry averages.
Validated in patient derived models
PYC uses scientific models derived from disease-affected patient cells to test our RNA therapeutics. This allows us to study the effects of our drug candidates on the target cells that carry the genetic mutation we are seeking to correct – providing a valuable insight into the potential efficacy of our therapeutics prior to dosing patients in clinical trials.